Skip to main content

Videos

Viewpoints
01/12/2026
Zwelithini Tunyiswa, BA; Ryan P. Dirks, PA-C
With tightening skin substitute reimbursement and increasing regulatory scrutiny, many are questioning whether mobile wound care remains sustainable. Drawing on real-world experience, this discussion reframes sustainability as a...
With tightening skin substitute reimbursement and increasing regulatory scrutiny, many are questioning whether mobile wound care remains sustainable. Drawing on real-world experience, this discussion reframes sustainability as a...
With tightening skin substitute...
01/12/2026
Wounds
Viewpoints
01/09/2026
Zwelithini Tunyiswa; Ryan P. Dirks, PA-C
In Part 2 of this interview series, Zwelithini Tunyiswa, BS, and Ryan Dirks, PA-C, of Open Wound Research confront the emotional and operational fallout of intensified fraud, waste, and abuse scrutiny in wound care—particularly as it relates...
In Part 2 of this interview series, Zwelithini Tunyiswa, BS, and Ryan Dirks, PA-C, of Open Wound Research confront the emotional and operational fallout of intensified fraud, waste, and abuse scrutiny in wound care—particularly as it relates...
In Part 2 of this...
01/09/2026
Wounds
Viewpoints
01/08/2026
Caroline E. Fife, MD, FAAFP, CWS, FUHM
Dr. Fife discusses the effects of CTP changes on hospital-based, mobile clinicians, skilled nursing and other settings, also touching on considerations with product handling.
Dr. Fife discusses the effects of CTP changes on hospital-based, mobile clinicians, skilled nursing and other settings, also touching on considerations with product handling.
Dr. Fife discusses the effects...
01/08/2026
Wounds
Viewpoints
01/06/2026
Zwelithini Tunyiswa; Ryan P. Dirks, PA-C
In part 1 of this interview series, Zwelithini Tunyiswa, BS, and Ryan Dirks, PA-C, of Open Wound Research examine how mobile wound care has been reshaped by the rapid rise of cellular and acellular matrix products (CAMPs)/skin substitutes.
In part 1 of this interview series, Zwelithini Tunyiswa, BS, and Ryan Dirks, PA-C, of Open Wound Research examine how mobile wound care has been reshaped by the rapid rise of cellular and acellular matrix products (CAMPs)/skin substitutes.
In part 1 of this interview...
01/06/2026
Wounds
Matthew Regulski, DPM, FFPM, RCPS (Glasgow), DABMSP
Viewpoints
12/30/2025
Matthew J. Regulski, DPM, ABMSP, CMET, FAPWH(c)
CMS reimbursement reforms are reshaping the use of skin substitutes in wound care, phasing out high-cost, low-evidence products in favor of therapies backed by rigorous clinical data. New models like WISeR promote prior authorization to...
CMS reimbursement reforms are reshaping the use of skin substitutes in wound care, phasing out high-cost, low-evidence products in favor of therapies backed by rigorous clinical data. New models like WISeR promote prior authorization to...
CMS reimbursement reforms are...
12/30/2025
Wounds
Viewpoints
12/29/2025
Diane G. Weiss, CPC, CPB, CCP, CHRI
This speaker discusses how CTP changes affect various stakeholders, how prepared providers will be, whether regulatory efforts are fostering or stifling innovation, and what policy actions would ensure sustainable growth and fair competition...
This speaker discusses how CTP changes affect various stakeholders, how prepared providers will be, whether regulatory efforts are fostering or stifling innovation, and what policy actions would ensure sustainable growth and fair competition...
This speaker discusses how CTP...
12/29/2025
Wounds
Viewpoints
12/26/2025
Nikolai Sopko, MD, PhD; Ned Swanson, MD
As recent policy changes reshape the wound care and biologics landscape, the 351 pathway is emerging as one for innovation, rigor, and clinical confidence. While demanding in time and resources, these speakers share that they expect this...
As recent policy changes reshape the wound care and biologics landscape, the 351 pathway is emerging as one for innovation, rigor, and clinical confidence. While demanding in time and resources, these speakers share that they expect this...
As recent policy changes reshape...
12/26/2025
Wounds
Viewpoints
12/24/2025
John Schroeder
The regulatory environment is "dramatically stifling our efforts to innovate," notes this speaker.
The regulatory environment is "dramatically stifling our efforts to innovate," notes this speaker.
The regulatory environment is...
12/24/2025
Wounds
Viewpoints
12/23/2025
Nikolai Sopko, MD, PhD; Ned Swanson, MD
The 351 regulatory pathway demands a highly structured, data-intensive clinical trial process that ensures alignment with the FDA and payers before the first patient is enrolled. One company is working to build rigorous pre-market evidence...
The 351 regulatory pathway demands a highly structured, data-intensive clinical trial process that ensures alignment with the FDA and payers before the first patient is enrolled. One company is working to build rigorous pre-market evidence...
The 351 regulatory pathway...
12/23/2025
Wounds
Viewpoints
12/22/2025
John Schroeder
In this video, the speaker discusses "frustration and confusion" in the industry regarding clinical trials and notes a possible delay in product release.
In this video, the speaker discusses "frustration and confusion" in the industry regarding clinical trials and notes a possible delay in product release.
In this video, the speaker...
12/22/2025
Wounds